MYGN - Myriad Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2022-12-31
2021-12-31
2020-06-30
2019-06-30
Total Revenue
661,400
678,400
690,600
638,600
851,100
Cost of Revenue
193,900
202,000
197,600
186,100
201,000
Gross Profit
467,500
476,400
493,000
452,500
650,100
Operating Expenses
Research Development
82,500
85,400
81,900
77,200
85,900
Selling General and Administrative
505,800
514,700
599,800
510,100
555,500
Total Operating Expenses
588,300
600,100
681,700
587,300
641,400
Operating Income or Loss
-120,800
-123,700
-188,700
-134,800
8,700
Interest Expense
2,800
3,200
6,600
10,800
12,000
Total Other Income/Expenses Net
-10,100
-16,300
137,500
-80,700
100
Income Before Tax
-132,000
-140,600
-57,100
-223,300
0
Income Tax Expense
-54,700
-28,600
-29,900
-23,700
-4,400
Income from Continuing Operations
-77,300
-112,000
-27,200
-199,600
4,400
Net Income
-77,300
-112,000
-27,200
-199,500
4,600
Net Income available to common shareholders
-77,300
-112,000
-27,200
-199,500
4,600
Basic EPS
-
-1.39
-0.35
-2.69
0.06
Diluted EPS
-
-1.39
-0.35
-2.69
0.06
Basic Average Shares
-
80,600
78,000
74,300
73,500
Diluted Average Shares
-
80,600
78,000
74,300
76,000
EBITDA
-
-84,700
12,300
-140,500
85,000